The role of the innate immune system in granulomatous disorders

Helen J. Petersen and Andrew M. Smith*

1 Eastman Dental Institute, University College London, London, UK
2 Department of Medicine, University College London, London, UK

The dynamic structure of the granuloma serves to protect the body from microbiological challenge. This organized aggregate of immune cells seeks to contain this challenge and protect against dissemination, giving host immune cells a chance to eradicate the threat. A number of systemic diseases are characterized by this specialized inflammatory process and granulomas have been shown to develop at multiple body sites and in various tissues. Central to this process is the macrophage and the arms of the innate immune response. This review seeks to explore how the innate immune response drives this inflammatory process in a contrast of diseases, particularly those with a component of immunodeficiency. By understanding the genes and inflammatory mechanisms behind this specialized immune response, will guide research in the development of novel therapeutics to combat granulomatous diseases.

Keywords: granuloma, Crohn’s, innate, macrophage, neutrophil, autophagy

INTRODUCTION

The innate immune system plays a central role in driving inflammation and protecting the body from invading microorganisms. This first line of defense is made up of white blood cells, secretory molecules, and proteins which form an anatomical barrier to infection. Components of the innate immune system are important for orchestrating granuloma formation in response to microbial and foreign body challenge. This specialized inflammatory process can occur throughout the body, varying in size, organization, and composition of innate immune cells involved. The ultimate function of the granuloma is to contain and eradicate microorganisms or chronic irritants that are resistant to elimination through the normal immune response. This process is finely balanced between host protection and localized collateral damage to normal tissue and potential loss of function.

An emerging concept that this specialized inflammatory process is in fact a last resort when other immune protective processes have failed is slowly becoming recognized. A number of immunodeficiency disorders hereditary and acquired, present with granulomatous inflammation at a variety of body sites. Granuloma formation in patients with these disorders often has an infective prequel. Failure to clear the infective organism results in persistence and subsequent granuloma formation to try to contain the infection. The aim of this review is to explore the role of the innate immune system and its aberrant disorders in the formation of the granuloma.

GRANULOMA FORMATION AND ROLE IN IMMUNODEFENSE

A granuloma is a collection of inflammatory cells, predominantly mature macrophages that form an aggregate in response to an antigen. This antigen can include invading bacteria, fungi, foreign bodies, and immune complexes (James, 2006; Schappi et al., 2008; Ramakrishnan, 2012). The purpose of the granuloma is to isolate this antigen from the body and to facilitate its eradication. This crucial immune reaction serves to protect the body from dissemination of the antigen, this being especially important in the case of mycobacterial infections. Immune defects, in particular ones that specifically affect the innate immune system have been shown to result in poor granuloma formation. Deficiency in tumor necrosing factor alpha (TNFα), Interleukin 12 (IL-12), or interferon gamma (IFNγ) also result in poor granuloma formation (Ramakrishnan, 2012).

On initiation of the granulomatous response, antigen presenting cells encountering an antigen release a cocktail of pro-inflammatory cytokines and chemoattractants. This recruits neutrophils from the circulation into the infected area and these in turn release additional cytokines to attract and activate monocytes. Under normal circumstances the recruited neutrophils eliminate the infective agent through the process of phagocytosis and digestion within the phagocytic vacuole (Segal, 2005). When the infective agent is resistant to neutrophil clearance macrophages engulf the antigen. Upon internalization, macrophages secrete additional pro-inflammatory mediators and attempt to digest the foreign body in order to present antigen derived peptides and lipids via MHC class II and CD1 molecules to T cells, natural killer T cells (NKT cells), and natural killer cells (NK cells). IFNγ secreted by NK cells, NKT cells, and T cells, activates dendritic cells. The dendritic cells in turn release copious amounts of TNFα to further promote the influx of immune cells to the area, creating a specialized microenvironment to deal with the foreign antigen (Figure 1A). Upon internalization of the antigen, macrophages secrete additional pro-inflammatory mediators and attempt to digest the foreign body in order to present antigen derived peptides and lipids via MHC class II and CD1 molecules to T antigen. The dendritic cells also migrate to the local lymph nodes to present the antigen to naïve CD4 cells. On secretion of IL-12 by dendritic cells,
these naïve cells differentiate into T-helper 1 (Th1) cells, which secrete IL-2 to promote their survival and expand their population. Activated Th1 cells enter the circulation and are attracted into the granuloma through the high levels of chemokines and adhesion molecules present on the macrovascular endothelial cells. They move about the granuloma using the macrophages as a scaffold to crawl over (Egen et al., 2008), the granuloma resembles a fluid bag rather than a "walled off" solid structure with cells freely moving within it (Savill and Fadok, 2000; Taylor et al., 2008).

Persistence of the antigen past this point leads to further chronicity of the inflammation and a mature granuloma. Complex cross talk between the individual immune cells and the surrounding epithelium via the production of high levels of TNF-α and IFN-γ leads to further maturation of macrophages. These macrophages become multinucleate giant cells, with increased phagocytosis and bacterial digestion capabilities. This is all aimed at trying to eradicate the antigen. After a number of weeks, these cells become terminally differentiated into epithelioid macrophages which contain large number of lysosomes, mitochondria, and are engaged in continued endocytic activity. Well-developed pseudopodia, allows for close interdigitation and a tightly packed aggregation of these enlarged cells. Finally, fibrosis occurs.

RELATION TO HUMAN DISEASE
A plethora of diseases in humans feature granulomatous inflammation including infective, neoplastic, vasculitic immunodeficiency states, and inflammopathies (Table 1). The rate of turnover of macrophages is key to the histological presentation of the granuloma. A highly toxic stimulus will result in macrophage death, such as seen in epithelioid granulomas. Examples of this are granulomas seen in tuberculosis and cat’s scratch disease. This results in constant influx of new macrophages to replace the dead cells. Whereas, an inert stimulus will result in a granuloma with low turnover of macrophages.

INFECTIVE GRANULOMAS
As the most frequent cause of granulomas, Mycobacterium tuberculosis has killed more people throughout history than any other infective disease (Lawn and Zumla, 2011). This suggests that tuberculosis granulomas are not always efficient at eradicating this pathogen. Tuberculosis infections often manifest themselves in immunodeficiency states, suggesting that the innate immune system is key to maintaining effective granuloma formation and eradication of M. tuberculosis. Recent research shows that this intracellular pathogen can exploit the innate immune system in the early stages of granuloma formation to facilitate its persistence and potential systemic dissemination. On inhalation M. tuberculosis is rapidly phagocytosed by resident lung macrophages. They quickly replicate inside the macrophages and are transported to the surrounding tissues inside these cells. To try and prevent further dissemination and to ultimately exterminate the microorganism, granuloma formation is initiated.

The importance of the innate immune system in tuberculous granuloma formation is highlighted by the zebrafish model. Zebrafish larvae do not have an adaptive immune system, yet still form highly organized granulomas. Imaging studies inside zebrafish have shown macrophages arriving at a forming

| Table 1 | Table of granulomatous disorders. |
| --- |
| **Granulomatous disease** |
| **1. INFECTIONS** |
| • Fungi |
| o Histoplasma |
| o Coccioides |
| o Blastomyces |
| o Sporothrix |
| o Aspergillus |
| o Cryptococcus |
| o Protozoa |
| o Toxoplasma |
| o Leishmania |
| o Metazoa |
| o Schistosoma |
| o Spirochetes |
| o T. pallidum |
| o T. carateum |
| o T. perunue |
| • Mycobacteria |
| o M. tuberculosis |
| o M. kansasii |
| o M. leprae |
| o M. marinum |
| o M. avian |
| o BCG vaccine |
| • Bacteria |
| o Brucella |
| o Yersinia |
| **2. VASCULITIS** |
| • Wegener’s granulomatosis |
| • Necrotizing sarcoidal |
| • Churg–Strauss |
| • Broncho centric |
| • Polyanteritis nodosa |
| • Lymphomatoid |
| • Giant cell arteritis |
| • Systemic lupus erythematosus |
| • Bechets disease |
| **3. IMMUNOLOGICAL ABERRATIONS** |
| • Crohn’s disease |
| • Orofacial granulomatosis |
| • Sarcoidosis |
| • Langerhan’s granulomatosis |
| • Hepatic granulomatous disease |
| • Primary biliary cirrhosis |
| • Blau’s syndrome |
| • Peyronie’s disease |
| • Immune complex disease |
| • Histiocytosis X |
| **4. CHEMICALS** |
| • Beryllium |
| • Zincium |
| • Silica |

(Continued)
granuloma formation as a protective mechanism to ensure its survival. TNFα was thought to play a central role in tuberculous granuloma formation as TNFα deficient mice showed poor granuloma formation. Studies in zebrafish have now shown this may not be the case as granulomas still form in the absence of TNFα, but are not maintained. Due to a lack of TNFα, macrophages are unable to effectively kill and digest the ingested Mycobacteria. The structure of the granuloma is lost in TNFα deficient animals when these overburdened macrophages die (Clay et al., 2008). The importance of TNFα in granuloma integrity is clearly illustrated in the reactivation of latent M. tuberculosis in humans undergoing anti-TNFα antibody therapy. Reactivation of infection is results from an impairment in bacterial containment due to the loss of a fully functional granuloma and reduced CD8+ T cell immunity during therapy (Miller and Ernst, 2009). Neutrophils also play a central role in the tuberculous granuloma with peak levels at 3 weeks after inoculation (Wolf et al., 2007). Failure of normal macrophage functioning in granuloma results in an increase of these cells in the granuloma. The consequence of impaired macrophage microbiocidal activity is the onset of necrosis which attracts neutrophils into the granuloma in response (Cooper et al., 1993; MacMicking et al., 2003). Increased neutrophil ingress has been shown to herald increased pathology in M. tuberculosis infections. Deficiency in caspase recruitment domain-containing protein 9 (CARD9) results in neutrophil-rich granulomas (Dorhoi et al., 2010; Redford et al., 2010). CARD9 mediates signals from so-called pattern-recognition receptors such as toll-like receptors (TLRs), NOD-like receptors (NLRs), and dectin-1 activate downstream pathways, including NF-κB. This subsequently induces the release of cytokines to stimulate/regulate the innate and adaptive immune responses. One such cytokine is the immunomodulator IL-10, essential for downregulation of IL-23 signaling and subsequent IL17 production. IL-17 is secreted by Th-17 and γδ T cells and leads to mass neutrophil influx into the granuloma (Lockhart et al., 2006). This is supported by the fact peak neutrophil influx occurs around day 21 and coincides with the activation of the adaptive immune response. In schistosome infection however, a Th-2 dominant response is mounted, absence of the Th-2 cytokine IL-4 results in increased hepatocyte damage, driven by excessive proinflammatory mediator secretion. This suggests the Th-2 response is protective for excessive immune stimulation and response to schistosome eggs (Pearce et al., 2004). Dorhoi et al. showed that CARD9 knockout mice failed to secrete IL-10 and produced neutrophilic granulomas due to increased IL-17 levels. These mice subsequently died from an aberrant excessive inflammatory response that resulted in the dissemination of the infection (Dorhoi et al., 2010). A role for CARD9 in the development of Crohn’s disease has also been highlighted through its identification in genome wide association studies (GWAS) (Franke et al., 2010).

**COMPLEX DISEASE OF ABERRANT IMMUNE FUNCTION**

**Sarcoidosis**

Sarcoidosis is a systemic disease affecting multiple systems, but particularly barrier tissues such as the lungs, eyes, and skin (Rastogi et al., 2011). Current research has suggested that both environmental and genetic factors play a role in this complex disease. A GWAS
conducted using 499 German individuals with sarcoidosis and 490 controls, detected an association to the ANXA11 (annexin 11) gene on chromosome 10q22.3 (Hofmann et al., 2008). This protein has been implicated in a number of functions including vesicle trafficking and apoptosis (Gerke and Moss, 2002). It is thought that the prevention of propagation of granulomatous inflammation is controlled by apoptotic mechanisms of inflammatory cells. It facilitates calcium dependent interaction with ALG-2 a glycosyltransferase, which is necessary for caspase cell-induced death (Rao et al., 2004). It is therefore possible if annexin 11 regulated apoptotic mechanisms are affected because of this mutation, activated inflammatory cells survive and drive the granulomatous response further to cause wide spread disease.

High levels of TNFα and IL-12 in the serum of patients with the disease has been shown and also increased production of these cytokines by peripheral blood monocytes and alveolar macrophages (Prior et al., 1996). Macrophages are important defense cells in the lungs and are critical for initiating an inflammatory response on stimulation by inhaled microbes and toxins. This is facilitated through recognition of pathogen-associated molecular patterns (PAMPs) through pattern-recognition receptors such as TLRs and NLRs. Rastogi et al. (2011) have shown that the high cytokine levels detected in patients with sarcoidosis is down to stimulation of alveolar macrophages with TLR4 and NOD1 agonists. This in turn leads to sustained p38 phosphorylation and cytokine production, particularly increased transcription of IL-12, TNFα, and IL-1 (Dong et al., 2002; Inoue et al., 2006). TNFα maintains the integrity and maintenance of the granuloma and limits the influx of inflammatory cells to the granuloma to prevent escalation of the inflammatory process.

Paradoxically, anti-TNFα induced sarcoidosis has also been reported in the literature, mainly affecting the lungs, parotid, and skin (Massara et al., 2010). After withdrawal of anti-TNFα therapy the condition resolves, it is thought that the cytokine imbalance experienced on prolonged TNFα blockade precludes the disease. Corticosteroid therapy has also been shown to be detrimental in recent onset disease (Reich, 2003, 2012).

Dendritic cells play a central role in granuloma formation by directly recruiting immune cells via TNFα secretion and indirectly through the activation of T cells via presentation of antigen in the surrounding lymph nodes. Patients with sarcoidosis have shown to present with a deficit in delayed type hypersensitivity reactions through impairment of dendritic cell functioning (Mathew et al., 2008). The same group also showed that sarcoid patients have comparable levels of circulating dendritic cells to that of healthy controls, but these dendritic cells display anergy to microbial challenge, despite the presence of upregulated costimulatory and maturation markers (Mathew et al., 2008). This dysfunction is mild and therefore does not predispose these individuals to severe microbial infections as seen with those with primary immunodeficiencies. The same group also demonstrated a correlation between the degree of dendritic cell dysfunction and severity of pulmonary disease.

It has also been suggested that Tuberculosis and sarcoidosis are different spectrums of the same disease (Gupta et al., 2012). The histological and clinical similarities of both diseases could point to the fact that sarcoidosis is immune hypersensitivity to mycobacterial antigens, whilst in patients with tuberculosis; an underactive immune process.

**Primary biliary cirrhosis**

Activation of the innate immune system in this organ specific autoimmune disorder is thought to be key in the early stages of this disease as seen by eosinophilic infiltrations and elevated IgM (Berg, 2011). Biliary epithelial cells express a number of pattern-recognition receptors and are the first line of defense against foreign invaders in the liver. They are repeatedly exposed to PAMPs and through TLR and NLR signaling eventually undergo apoptosis. It is hypothesized that increased activation of apoptosis within these cells is via loss or down regulation of Bcl-2 and this in turn plays a major role in the disease process (Garchon et al., 1994). Poor clearance of these apoptotic and damaged cells by macrophages leads to their persistence and subsequent stimulation of the adaptive immune response and the tissue damage and granuloma formation that ensues, which is thought to be the primary mechanism driving the disease process. Particularly, exposure of mitochondrial membrane proteins leads to production of antimicrobial autoantibodies (AMAs) which are a feature of the disease. This can lead to development of concomitant autoimmune disorders (Watt et al., 2004). The balance between bile duct proliferation and damage is the hallmark of this disease process which affects biliary epithelial cells.

**GRANULOMA FORMATION IN IMMUNODEFICIENCY STATES**

A number of immunodeficiency disorders present with granulomatous inflammation, including hereditary immunodeficiency states such as common variable immunodeficiency and chronic granulomatous disease (CGD). Diseases which present with granulomas such as Crohn’s disease have also recently been shown to have an element of immunodeficiency (Rahman et al., 2008).

**Crohn’s disease**

One of the most common causes of granuloma formation in the gastrointestinal tract is the inflammatory bowel disorder; Crohn’s disease. Granulomas in Crohn’s patients can occur anywhere along the gastrointestinal tract from the mouth to the rectum. A complex interplay between the microbial contents, estimated to be 10^14 bacteria, the epithelium and immune components drives this disease process. The gastrointestinal tract has a multi-layered defense system which consists of physical barriers, anti-bacterial molecules, and a range of leukocytes. Epithelial goblet cells secrete mucus, which act as a barrier to invading bacteria, whilst paneth cells secrete defensins which are primitive microbialic peptides. Innate immune cells such as macrophages and dendritic cells are present in the lamina propria for immunosurveillance. It is thought that a breakdown in this complex homeostasis between the gut microflora and host defense mechanisms is the precipitating cause to Crohn’s (Marks and Segal, 2008). A major hypothesis centers on the impaired handing and clearance of luminal content which gains access into the bowel wall (Sewell et al., 2009). The precise mechanisms responsible for this impaired innate immune response are still not fully understood. Recent GWAS (Barrett et al., 2008; Franke et al., 2010) have identified over 70 genetic polymorphisms associated with Crohn’s and this number is expected to
increase over the next few years (Lees et al., 2011). Many of these loci have been linked to genes involved in bacterial recognition, innate immunity, and autophagy. Interestingly a large proportion of the genes identified are also associated with other immune conditions illustrating common pathological processes in quite different phenotypes (Lees et al., 2011).

Genome wide association studies have identified several genes associated with autophagy (ATG16L1, IRGM, LRRK2, ULK1, and NOD2) (Levine and Deretic, 2007). NOD2 is the most strongly associated gene with Crohn’s disease responsible for pro-inflammatory cytokine release and autophagy induction (Hugot et al., 2001; Ogura et al., 2001; Travassos et al., 2010). Expressed predominantly by macrophages, NOD2 recruits another Crohn’s associated protein ATG16L1 to the cell membrane and acts as a sensor for bacterial peptidoglycan smallest subunit N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) and activating autophagy machinery (Torok et al., 2009). Numerous genetic studies have identified three NOD2 polymorphisms rs2066844 (R702W), rs2066845 (G908R), and rs2066847 (1007fs) as being associated with increased susceptibility for Crohn’s disease, common to all three is a loss in MDP sensitivity and an inability to activated downstream targets, thus inducing an immunodeficiency in carriers (Burton et al., 2007; Franke et al., 2010). ATG16L is expressed in the epithelial cells of the intestine, in leukocytes, and the spleen (Fujita et al., 2008). Studies have shown that mutation of ATG16L (T300A) has an association with the formation of ileal Crohn’s disease (Prescott et al., 2007; Sventoraityte et al., 2010).

The mechanism of autophagy within the gut and has a number of functions to maintain homeostasis. The first of these is intracellular defense against microorganisms via the process of xenophagy (Gardet and Xavier, 2012). This is thought to be important in the tight control of the innate immune response against commensals gut organisms. If this process is affected and bacterial handling impaired, this can lead to an inappropriate host inflammatory response against commensal organisms. Some of these genes (IRGM, NOD2, LRRK2) are also associated with infective granulomatous disorders, thus suggesting Crohn’s patients may have altered control of mycobacterial infections (Intemann et al., 2009; Kumar et al., 2010). Autophagy proteins have also been shown to be involved in the regulation of the inflammasome through defects in mitochondrial autophagy leading to increase reactive oxygen species and loss of regulation of inflammasome pathways, particularly the pro-IL-1β pathway. Plantinga et al. (2011) demonstrated that mutation in ATG16L results in monocytes with increased IL1β secretion on stimulation with MDP. Dendritic cells also rely on autophagy for antigen presentation (Schmid et al., 2007). Recent evidence has suggested that defects in autophagy proteins may destabilize the immune cross talk between dendritic cells and T cells leading to an increased inflammatory response (Wildenberg et al., 2012). It can be assumed that this could add to the collateral damage caused by the immune system within the gut. The last function of autophagy is maintenance of secretory granules in paneth cells, which have a role in innate immune defense in the gut. NOD2 and ATG16L are expressed by paneth cells, and through NLR and TLR signaling pathways these cells release a cocktail of antimicrobial proteins, including lysozyme, but principally they secrete alpha defensins. These hydrophobic peptides are pore forming units that disrupt bacterial cell membrane leading to lysis and death. The 1007fs mutation in NOD2 has been proven to decrease defensin expression and this is supported by the observation that patients with NOD2 mutations have lower defensins titers in ileostomy fluid compared to controls (Wehkamp et al., 2003; Van Limbergen et al., 2007). Lower levels of these proteins could facilitate entry of bacteria into the epithelial cells and a breach in the mucosal integrity. The T300A mutation in ATG16L also results in a decrease in secretory granule number within paneth cells. This loss of the mucosal barrier is the first step in the suggested multistep pathogenesis of Crohn’s (Marks and Segal, 2008). The next step involves reduction in bacterial killing capacity and clearance by neutrophils (Figure 1B).

Neutrophils play a central role in bacterial clearance from the gut and in the etiopathogenesis of Crohn’s. The importance of neutrophils in gut immunity becomes clear when you consider monogenic diseases that result in neutrophil dysfunction and the high incidence in bowel inflammation in these patients. These diseases are covered in more detail in the following section and a recent review (Rahman et al., 2008). A profound defect in the recruitment of neutrophils into tissues after stimulation with heat killed Escherichia coli and the subsequent failure to adequately clear this bacterial challenge has been identified in patients with Crohn’s disease (Smith et al., 2009). The neutrophils themselves function normally, but impaired cytokine secretion from macrophages results in their failure to accumulate in adequate numbers in the tissues (Marks et al., 2006; Smith et al., 2009). The consequence of this delayed recruitment results in bacteria remaining in the tissue, macrophages engulf the remaining bacteria and fecal matter inciting an inflammatory response culminating in granuloma formation. The defect is within the macrophage, specifically the vesicular trafficking and secretion of cytokines. Gene transcription and synthesis of TNFα was found to be normal in macrophages of Crohn’s disease patients, but secreted levels were grossly attenuated as a result of defective intracellular trafficking (Smith et al., 2009).

IL23R is another gene with several SNPs associated with Crohn’s disease (Duerr et al., 2006) as well as members of the IL23 pathway; Jak2 and STAT3 (Barrett et al., 2008). Secreted by activated dendritic cells, macrophages and monocytes, IL23 induces the development of TH17 cells and induces IL1, IL6, and TNFα from macrophages and monocytes. Primary immunodeficiencies characterized by mutations in IL23 pathway genes also present with granulomatous inflammation (see Table 2).

All these disorders have defects with the innate immune response and form granulomas in various tissues throughout the body.

The association of genes in autophagy regulation, IL–23 pathway, and defects in bacterial handling lends itself to the formation of the hypothesis that Crohn’s results from a defect in the digestion and removal of bacteria from the tissue. The remaining bacteria are walled off in the tissue and a granuloma forms to restrict dissemination of any infective agents. The granuloma then secretes pro-inflammatory cytokines and presents antigens to the adaptive immune system resulting in T cell activation. This response drives a chronic inflammatory condition which is the hallmark of
Table 2 | Immunodeficiency disorders that present with granulomatous inflammation.

| Disease                     | Gene                      | Inheritance                      | Granuloma location                                      | Reference                  |
|-----------------------------|---------------------------|----------------------------------|----------------------------------------------------------|----------------------------|
| Hermansky–Pudlak syndrome   | HPS-1, HPS-3, 10q23.1-23.3 | Autosomal recessive              | GI tract                                                 | Schinella et al. (1980)    |
| Chronic granulomatous disease | NCF1, NCF2, CYBA, and CYBB | X-linked or autosomal recessive   | Liver, mouth, skin, lungs, urinary tract, GI tract       | Segal et al. (1978)        |
| Chediak–Higashi disease     | CHS1 (LYST), 1q42-43      | Autosomal recessive              | GI tract                                                 | Ishii et al. (1987)        |
| RAG deficiency              | RAG1, RAG2 genes          | Autosomal recessive              | Cutaneous, mucous membranes, and internal organs         | Schuetz et al. (2008)      |
| Artemia deficiency (SCID-Athabascan) | DCLRE1C                  | Autosomal recessive              | Cutaneous                                                | IJspeert et al. (2011)     |
| Janus kinase 3 (Jak3) deficiency | ILR2G                    | Autosomal recessive form of severe combined immunodeficiency (SCID) | Cutaneous                                                 | Gregoriou et al. (2008)    |
| Griscelli syndrome          | RAB27a                    | Autosomal recessive              | Cutaneous                                                | Eyer et al. (1998)         |
| Common variable immunodeficiency (CVID) | ICOS, TNFRSF13B (encoding TACI), TNFRSF13C (encoding BAFF-R), and CD19. | Autosomal recessive and dominant forms                    | Lung, liver, skin, heart, eyes, gastrointestinal tract, and splenic granulomas | Ardeniz and Cunningham-Rundles (2009) |
| Ataxia telangiectasia       | A-T mutated gene (11q22-23) | Autosomal recessive              | Cutaneous granulomas                                    | Chiam et al. (2011)        |
| Nijmegen breakage syndrome (NBS) | nbs1(8q21)                 | Autosomal recessive              | Cutaneous                                                | Yoo et al. (2008)          |
| TAP deficiency/bare lymphocyte syndrome type 1 group 3 (BLS) | tap1 tap 2 genes | Autosomal recessive              | Necrotizing cutaneous, gut and lung granulomas          | Moins-Teisserenc et al. (1999), Zimmer et al. (2005) |
| Wiskott–Aldrich syndrome    | WAS gene, on the X-chromosome (Xp11.23-p11.22) | X-linked recessive               | Cutaneous                                                | Sebire et al. (2003)      |
| Hyper IgM                   | CD40L gene long arm of the X-chromosome (Xq26-27.2) | X-linked recessive (autosomal recessive and dominant forms) | Cutaneous                                                | Gallerani et al. (2004)    |

Crohn’s disease and the focus of the majority of current therapeutic agents. Future drug design could target the defective bacterial clearance by boosting macrophage function and subsequently reducing granuloma formation which may prove advantageous.

Monogenic disorders of neutrophil function

Although neutrophil defects do not appear to be the primary cause of Crohn’s, disorders which result in low neutrophil numbers such as cyclical neutropenia, disorders of bacterial digestion such as CGD and disorders of impaired vesicle trafficking and expulsion (Chediak–Higashi and Hermansky–Pudlak syndromes), can present with a Crohn’s-like gut. This includes granuloma formation in the lamina propria and ulceration. Approximately half of all CGD patients develop bowel inflammation which is indistinguishable from Crohn’s disease (Marks et al., 2009). These observations support the important role of neutrophils in healthy gut maintenance and a reduction of functioning in granuloma formation.

Chronic granulomatous disease affects primarily males and is a rare congenital disease that is either X-linked or autosomal recessive (Holland, 2010). This disorder is characterized by a defect in the superoxide generating NADPH oxidase system in neutrophils which is necessary for killing microorganisms by respiratory burst. The pathognomonic feature of CGD is recurrent infections, particularly by catalase positive bacteria and fungi (Martire et al., 2008). This impaired bacterial killing leads to granuloma formation in a variety of organs including the liver, gut, skin, and mouth (Levine et al., 2005). Defects of the proteins which are responsible for governing the respiratory burst to generate reactive oxygen species have been identified as the cause of this condition (Dinauer et al., 1987; Volpp et al., 1988; Clark et al., 1989). An unbalance in the expression of innate immune receptors on neutrophils has also been shown to have a causal role in CGD. Neutrophils in CGD patients show reduced expression of TLR5, TLR9, and CD18, reduced TLR5 levels resulting in reduced activation by bacterial flagella. Lowered CD18
expression results in impaired killing of Staphylococcus aureus. Both TLR5 and TLR9 expression levels have been shown to correlate with the severity of the disease, higher expression seen in patients with higher residual NADPH oxidase and a less severe phenotype (Rieber et al., 2012). Many CGD patients suffer from concomitant autoinflammatory conditions such as systemic lupus erythematosi and pulmonary fibrosis, potentially suggesting an uncontrolled inflammatory response tipping toward hyperinflammation (Winkelstein et al., 2000; Rieber et al., 2012). Upregulation of several pro-inflammatory genes has been identified by microarray analysis on activation of TLR2 or TLR4, which is independent of NADPH oxidase activity (Kobayashi et al., 2004; Bylund et al., 2007). In addition to the neutrophil the NADPH oxidase system is utilized by the macrophage and defective immune responses

![FIGURE 1](https://www.frontiersin.org)
Figure 1 | (A) Diagram of a mature granuloma. After 3 weeks of maturation, the granuloma is fully formed. Crosstalk between various cells of the immune system leads to proliferation of lymphocytes, predominantly T-helper cells. (a) Macrophages engulf the antigen and secrete pro-inflammatory cytokines. They also present antigen derived peptides and lipids via MHC class II and CD1 molecules to T cells, natural killer T cells (NKT cells), and natural killer cells (NK cells). (b) Th1 cells secrete IFNγ which activates dendritic cells. (c) Dendritic cells loaded with antigen migrate to the local lymph nodes where they present to naive CD4+ T cells. (d) Within the lymph node, the dendritic cells secrete IL-12 which stimulates these naive cells to differentiate into Th1 cells. These in turn secrete IL2 to expand their population. (e) At the granuloma site, activated dendritic cells secrete copious amounts of TNFα which activates the endothelium, upregulating the number of adhesion molecules to allow extravasation of Th1 cells and monocytes. (f) Th1 cells secrete IFNγ which stimulates monocytes to differentiate into macrophages. (B) Diagrammatic representation of the multistep pathogenesis of Crohn's disease. (1) Loss of integrity in the gut epithelium allows bacteria to leave the lumen and enter the tissue of the gut. (2) Defective autophagy. (3) Mutation of NOD2 leads to reduced secretion of pro-inflammatory cytokines including TNFα. (4) Defect in Neutrophil function (monogenic diseases) or reduced chemotaxis (inherited or due to reduced TNFα secretion). This leads to persistence of bacteria in the tissues. (5) Mutational the IL23R on Th17 cells leads to increased survival of these cells and increased IL17 production. High levels of IL17 is associated with increased bowel inflammation in Crohn's. (6) Mutation of ATG16L (T300A) leads to a excessive of production of IL1β. (7) Mutation in NOD2 leads to reduced defensin production by intestinal Paneth cells.
are also evident in CGD patients (Rahman et al., 2009). Impaired macrophage function is also evident in CGD, with attenuated pro-inflammatory cytokine and increased IL-10 secretion following bacterial stimulation. The role this plays in the development of granulomatous inflammation is still unclear.

**AUTOINFLAMMATORY STATES**

Blau syndrome is another immune disease which features granuloma formation. This rare autosomal dominant disorder can be characterized by granulomatous polyarthritis, uveitis, macropapular skin lesions containing granulomas and cranial neuropathies. Crohn’s-like disease occurs in 30% of patients (Geha et al., 2007). A missense mutation in NOD2 drives this disease resulting in a gain of function and periodic episodes of fever and inflammation classic of this disorder (Fritz et al., 2006). This is a direct opposite of the loss of function seen in NOD2 associated with Crohn’s disease, although both conditions result in granuloma formation. Monoocytes derived from patients with Blau syndrome after stimulation with macrophage colony-stimulating factor had a greater ability to form multinucleate giant cells compared to healthy controls (Yasui et al., 2010). Macrophages also displayed increased adherence and expression of inter-cellular adhesion molecule-1 (ICAM1), which could suggest an increase in ability for macrophage fusion and giant cell generation.

Blau syndrome granulomas are immunohistochemically distinct from those of Sarcoidosis or Crohn’s. A thick halo of lymphocytes, particularly Th17 cells surrounds the macrophages (Rose et al., 2011). Another observation in Blau syndrome granulomas is the phagocytosis of lymphocytes which can be found with their cytoplasm intact within the multinucleate giant cells of the granuloma. The gain of function of NOD2 and its role in autophagy could explain this phenomenon. Granulomas in patients with Crohn’s disease there is an absence of this halo of lymphocytes and an increase in neutrophils and sclerosis in the surrounding tissue (Janssen et al., 2012).

**SUMMARY**

Our understanding of the complex mechanisms that underlie granuloma formation and maintenance is growing, particularly the role of the innate immune system. Genetic studies have identified that many diseases of immune aberration and granuloma formation share common genetic backgrounds (Lees et al., 2011). Although, many of these diseases have multiple causal mutations associated with the disease process. Understanding the genetic overlap between these diseases is key to elucidating common pathways and mechanisms for the disease process in this specialized inflammatory response.

The key to finding new treatment strategies to combat granulomatous disorders lies with understanding the genetic and immunological background to immunodeficiency diseases that result in granuloma formation. Insight into the complex immune signaling pathways which drive these diseases will hopefully in turn highlight appropriate targets for novel therapeutic therapies. The fact that granuloma formation is associated with immunodeficiency states and also can be initiated in some diseases by immunomodulatory drugs highlights the need for caution in prescribing immunosuppressants to treat granulomatous diseases.

**ACKNOWLEDGMENTS**

HJP is funded by the small grants scheme from the Dental Faculty of the Royal College of Surgeons of England.

**REFERENCES**

Ardeniz, O., and Cunningham-Rundles, C. (2009). Granulomatous disease in common variable immunodeficiency. Clin. Immunol. 133, 198–207.

Barrett, J. C., Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rieux, J. D., et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40, 955–962.

Berg, P. A. (2011). The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view. Liver Int. 31, 920–931.

Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., et al. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678.

Bylund, J., MacDonald, K. L., Brown, K. L., Mydel, P., Collins, L. V., Hancock, R. E. W., et al. (2007). Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. Eur. J. Immunol. 37, 1087–1096.

Chiam, L. Y. T., Verhagen, M. M. M., Haraldsson, A., Wulfraat, N., Driessen, G. J., Neeta, M. G., et al. (2011). Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: reflection of inappropriate immune regulation? Dermatology 223, 13–19.

Clark, R. A., Malech, H. L., Gallin, J. I., Niuno, H., Volpp, B. D., Pearson, D. W., et al. (1989). Genetic-variants of chronic granulomatous disease – prevalence of deficiencies of 2 cytosolic components of the NADPH oxidase system. N. Engl. J. Med. 321, 647–652.

Clay, H., Volkman, H. E., and Ramakrishnan, L. (2008). Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29, 283–294.

Cooper, A. M., Dalton, D. K., Stewart, T. A., Griffin, J. P., Russell, D. G., and Orme, I. M. (1993). Disseminated tuberculosis in interferon-gamma-disrupted mice. J. Exp. Med. 178, 2243–2247.

Davis, J. M., Clay, H., Lewis, J. L., Ghorii, N., Herbolz, P., and Ramakrishnan, L. (2002). Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17, 693–702.

Din auer, M. C., Orkin, S. H., Brown, R., Jesaitis, A. J., and Parkos, C. A. (1987). The glycoprotein encoded by the X-linked chronic granulomatous-disease locus is a component of the neutrophil cytochrome-b complex. Nature 327, 717–720.

Dong, C., Davis, R. J., and Flavell, R. A. (2002). MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55–72.

Dorhoi, A., Desel, C., Yerecnev, V., Pradi, L., Brinkmann, V., Mollenkopf, H. J., et al. (2010). The adaptor molecule CARD9 is essential for tuberculosis control. J. Exp. Med. 207, 777–792.

Duerr, R. H., Taylor, K. D., Brant, S. R., Rieux, J. D., Silverberg, M. S., Daly, M. J., et al. (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463.

Egen, J. G., Rothfuchs, A. G., Feng, C. G., Winter, N., Sher, A., and Germain, R. N. (2008). Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28, 271–284.

Eyer, D., Petiau, P., Finck, S., Heid, E., Grosshans, E., and Lutz, P. (1998). Cutaneous granulomatous lesions in a patient with Griscelli syndrome. Annals of Dermatology et Venerologie 125, 727–728.

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., et al. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat. Genet. 42, 1118.
Fritz, J. H., Ferrero, R. L., Philpott, D. J., and Girardin, S. E. (2006). Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7, 1250–1257.

Fujita, N., Ishi, T., Omori, H., Fukuda, M., Noda, T., and Yoshimori, T. (2008). The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol. Biol. Cell 19, 2092–2100.

Gallerani, I., Innocenti, D. D., Corsonella, G., Berti, S., Amato, L., Moretti, S., et al. (2004). Cutaneous sarcoid-like granulomas in a patient with X-linked hyper-IgM syndrome. Pediatr. Dermatol. 21, 39–43.

Garchon, H. J., Luan, J. J., Eloy, L., Bedossa, P., and Bach, J. F. (1994). Genetic analysis of immune dysfunction in non-obese diabetic (NOD) mice – mapping of a susceptibility locus for sarcoidosis. Eur. J. Immunol. 24, 380–384.

Gardet, A., and Xavier, R. J. (2012). Common alleles that influence autophagy and the risk for inflammatory bowel disease. Curr. Opin. Immunol. 24, 522–529.

Geha, R. S., Notarangelo, L. D., Casanova, J. L., Chapel, H., Conley, M. E., Fischer, A., et al. (2007). Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J. Allergy Clin. Immunol. 120, 776–794.

Gerke, V., and Moss, S. E. (2002). Annexins: from structure to function. Physiol. Rev. 82, 331–371.

Gregoriou, S., Trimmis, G., Charissi, C., Kaloferomilos, D., Stefanaki, S., and Rigopoulos, D. (2008). Cutaneous granulomas with predominately CD8(+) lymphocytic infiltrate in a child with severe combined immunodeficiency. J. Cutan. Med. Surg. 12, 246–248.

Gupta, D., Agarwal, R., Aggarwal, A. N., and Jindal, S. K. (2012). Sarcoidosis and tuberculosis: the same disease with different manifestations or similar manifestations of different disorders. Curr. Opin. Pulm. Med. 18, 506–516.

Hofstra, W. S., Franke, A., Fischer, A., Jacobs, G., Nothnagel, M., Gaede, K. I., et al. (2008). Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat. Genet. 40, 1103–1106.

Holland, S. M. (2010). Chronic granulomatous disease. Clin. Rev. Allergy Immunol. 38, 3–10.

Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, I. P., Beliche, J., et al. (2001). Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 416, 599–603.

Ilspeert, H., Lankest, A. C., van den Berg, J. M., Wiegant, W., van Zelm, M. C., et al. (2011). Artemis splice defects cause atypical SCID and can be restored in vitro by an antisense oligonucleotide. Gene Immun. 12, 434–444.

Inoue, T., Boyle, D. L., Corr, M., Hamaker, D., Davis, R. J., Flavell, R. A., et al. (2006). Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc. Natl. Acad. Sci. U.S.A. 103, 5484–5489.

Intemann, C. D., Tyie, T., Niemann, S., Browne, E. N. L., Chinbuah, M. A., Enum, A., et al. (2009). Autophagy gene variant IRGM-261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog. 5:e1000577. doi:10.1371/journal.ppat.1000577

Ishii, E., Matu, T., Iida, M., Inamitu, T., and Ueda, K. (1987). Chediak-Higashi syndrome with intestinal complication - report of a case. J. Clin. Gastroenterol. 9, 356–558.

James, D. G. (2000). A clinicopathological classification of granulomatous disorders. Postgrad. Med. J. 76, 457–465.

Janssen, C. E. I., Rose, C. D., De Hertogh, S. D., and Zumla, A. I. (2011). Primary immunodeficiency defects cause atypical SCID and can contribute to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS Pathog. 5:e1000577.

Kumar, D., Nath, L., Kamal, M. A., Mathew, S., Bauer, K. L., Fischoeder, A., et al. (2011). Artemis splice defects cause atypical SCID and can be restored in vitro by an antisense oligonucleotide. Gene Immun. 12, 434–444.

Kum, D. E., Stowe, J. M., Higashi-syndrome with intestinal complications. J. Clin. Pathol. 12, 246–248.

Lees, C. W., Barrett, J. C., Parkes, M., and Satzangi, J. (2011). New IBD genetics: common pathways with other diseases. Gut 60, 1739–1753.

Levine, B., and Deretic, V. (2007). Unveiling the roles of autophagy in innate and adaptive immunity. Nat. Rev. Immunol. 7, 767–777.

Levine, S., Smith, V. C., Malone, M., and Seibele, N. J. (2005). Histopathological features of chronic granulomatous disease (CGD) in childhood. Histopathology 47, 508–516.

Lockhart, E., Green, A. M., and Flynn, J. L. (2006). IL-17 production is dominated by gamma delta T cells rather than CD4 T cells during CD4 T cell survival. J. Immunol. 177, 1724–1734.

Marks, D. J., Harbord, M. W. N., MacAllister, R., Rahman, F. Z., Young, J., Al-Lazikani, B., et al. (2006). Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet 367, 666–670.

Marks, D. J. B., Miyagi, K., Rahman, F. Z., Novelli, M., Bloom, S. L., and Segal, A. W. (2009). Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am. J. Gastroenterol. 104, 117–124.

Marks, D. J. B., and Segal, A. W. (2008). Innate immunity in inflammatory bowel disease: a disease hypothesis. J. Pathol. 214, 260–266.

Martire, B., Ronelli, R., Seresina, A., Pignata, C., Broccoli, T., Finocchi, A., et al. (2008). Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin. Immunol. 126, 155–164.

Massara, A., Cavazzini, L., La Corte, R., and Trottta, F. (2010). Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin. Arthritis Rheum. 39, 313–319.

Mathew, S., Bauer, K. L., Fischoeder, A., Bhat, N., and Oliver, S. J. (2008). The anergic state in sarcoidosis is paradoxical. J. Clin. Invest. 121, 1229–1235.

Mays, T., Prior, C., Knight, R. A., Herold, M., Ott, G., and Spiteri, M. A. (1996). Pulmonary sarcoidosis: patterns of cytokine release in vitro. Eur. Respir. J. 9, 47–53.

Miller, E. A., and Ernst, J. D. (2009). Severe combined immunodeficiency diseases. Inflammatory Bowel Dis. 14, 1434–1452.

Rao, R. V., Poksay, K. S., Castro-Oregbon, S., Schilling, B., Row, R. H., del Rio, G., et al. (2004). Mucosal components of a cell death pathway activated by endoplasmic reticulum stress. J. Biol. Chem. 279, 177–187.

Rastogi, R., Du, W. J., Ju, D. H., Pirocksi, G., Liu, Y. S., Nunez, G., et al. (2011). Dysregulation of p38 and MKP-1 response to NOD1/TLR4.
stimulation in sarcoid bronchoalveolar cells. Am. J. Respir. Crit. Care Med. 183, 500–510.

Redford, P. S., Boonstra, A., Read, S., Pitt, J., Graham, C., Stavropoulos, E., et al. (2010). Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur. J. Immunol. 40, 2200–2210.

Reich, J. M. (2003). Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 20, 227–234.

Reich, J. M. (2012). On the nature of sarcoidosis. Eur. J. Intern. Med. 23, 105–109.

Rieber, N., Hector, A., Kuijpers, T., Schmid, D., Pypaert, M., and Munz, C. (2012). Autophagosomes in sarcoid bronchoalveolar cells. Eur. J. Clin. Pharmacol. 68, 411–418.

Savill, J., and Fadok, V. (2000). Corpse clearance defines the meaning of cell death. Nature 407, 784–788.

Schappi, M. G., Defert, C., Fisette, L., Gavazzi, G., Herrmann, F. R., Belli, D. C., et al. (2008). Branched fungal beta-glucan causes hyperinflammation and necrosis in phagocytes NADPH oxidase-deficient mice. J. Pathol. 214, 434–444.

Schinella, R. A., Greco, M. A., Cobert, B. L., Denmark, L. W., and Cox, R. P. (1980). Hermansky-Pudlak Syndrome with Granulomatous Colitis. Ann. Intern. Med. 92, 20–23.

Schmid, D., Pypaert, M., and Munz, C. (2007). Antigen-loading compartments for major histocompatibility complex II molecules continuously receive input from autophagosomes. Immunity 26, 79–82.

Schuetz, C., Huck, K., Gadowius, S., Megahed, M., Feyen, O., Hubner, B., et al. (2008). An immunodeficiency with RAG mutations and granulomas. N. Engl. J. Med. 358, 2030–2038.

Sehne, N. I., Haselden, S., Malone, M., Davies, E. G., and Ramsay, A. D. (2003). Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphotropic granulomatosis and responsive to anti-CD20 immunotherapy. J. Clin. Pathol. 56, 555–557.

Segal, A. W. (2003). How neutrophils kill microbes. Annu. Rev. Immunol. 21, 193–227.

Segal, A. W., Webster, D., Jones, O. T. G., and Allison, A. C. (1978). Absence of a newly described cytokrome-B from neutrophils of patients with chronic granulomatous disease. Lancet 2, 446–449.

Sewell, G. W., Marks, D. J. B., and Segal, A. W. (2009). The immunopathogenesis of Crohn’s disease: a three-stage model. Curr. Opin. Immunol. 21, 506–513.

Smith, A. M., Rahman, F. Z., Hayee, S., Graham, S. J., Marks, D. J. B., Sewell, G. W., et al. (2009). Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J. Exp. Med. 206, 1883–1897.

Sventoraityte, J., Zvirbliene, A., Franke, C. H. (2011). Blau syndrome revisited. Curr. Opin. Rheumatol. 23, 411–418.

Van Limbergen, J., Russell, R. K., Megahed, M., Feyen, O., Hubner, B., and Allison, A. C. (1978). Absence of a newly described cytokrome-B from neutrophils of patients with chronic granulomatous disease. Lancet 2, 446–449.

Verhaar, A. P., de Veelde, A. A., et al. (2007). Autoimmune pancreatitis associated with NOD2 and IL23R polymorphisms and variants in ATG16L1. Gut 56, 719–727.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 January 2013; accepted: 05 May 2013; published online: 24 May 2013.

Citation: Petersen HJ and Smith AM (2013) The role of the innate immune system in granulomatous disorders. Front. Immunol. 4:120. doi: 10.3389/fimmu.2013.00120

This article was submitted to Frontiers in Inflammation, a specialty of Frontiers in Immunology.

Copyright © 2013 Petersen and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.